Rethinking Lipoprotein(a) Trial Design: The Case for Phenotype-Guided Enrichment
Lipoprotein(a) [Lp(a)] is an unusual cardiovascular risk factor.Its plasma concentration is largely genetically determined, is essentially fixed from early childhood, and is barely influenced by lifestyle or the more commonly used lipid-lowering drugs.Epidemiological, genetic and Mendelian randomisation studies converge on a causal role in both atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis [1-3].Around one in five people of European ancestry carry levels above 105 nmol/L, which per se are considered a cardiovascular risk-enhancing factor, and guidelines on both sides of the Atlantic now recommend measuring Lp(a) at least once in every adult [1,4,5].Yet, until now, there has been no targeted treatment to offer those found to be at risk.
Authors
- Carlos Aguíar (ORCID: https://orcid.org/0000-0002-5970-6353)
Publication Details
- Journal
- European Journal of Preventive Cardiology
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1093/eurjpc/zwag593
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00